The Federal Trade Commission has filed an amicus brief in a class action that questions whether brand name drug companies can pay generic rivals to stay out of the market until a patent expires.
According to the FTC, which files only a handful of amicus briefs each year, such agreements cost consumers $3.5 billion per year by depriving them of generic alternatives to brand-name drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
